1. Коротько Г.Ф., Корочанская Н.В. Постпрандиальные гемодинамические реакции. Тер. арх. 1998; 70 (2): 5–8.
2. Тюрина Т.В. Постпрандиальная гипотензия. Врач. 2002; 12: 24–6.
3. Чазова И.Е., Ратова Л.Г. Роль суточного мониторирования артериального давления в оценке эффективности антигипертензивной терапии. Consilium Medicum 2007; 1: 18–26.
4. Aronow W, Frishman WH. Treatment of hypertension and prevention of ischemic stroke. Curr Cardiol Rep 2004; 6: 124–9.
5. Battershill PE, Clissold SP. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Source Drugs 1990; 38 (5): 658–702.
6. Becket N, Ruth Peters ChB. Treatment of Hypertension in Patients 80 Years of Age or Older. Published at www.nejm.org March 31, 2008.
7. Bertinieri G, Grassi G, Rossi P et al. A 24-hour blood pressure profile in centenarians J Hypertens 2002; 20 (9): 1765–9.
8. Edwards BJ, Perry HM, Kaiser FE et al. Relationship of age and calcitonin gene – related peptide to postprandial hypotension. Mech Ageing Dev 1996; 87 (2): 61–73.
9. Ferrari AU. Modifications of the cardiovascular system with aging. Am J Geriatr Cardiol 2002; 11 (1): 30–3.
10. Grodzicki T. Ambulatory blood pressure monitoring and postprandial hypotension in elderly patients with isolated systolic hypertension. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Hum Hypertens 1998; 12: 161–5.
11. Gueyffier F, Bulpitt C, Boissel J-P et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. INDANA Group. Lancet 1999; 353: 793–6.
12. Isa K, Tokashiki T, Tana T et al. A case of hemodynamic brain infarction with postprandial hypotension Rinsho. Shinkeigaku 2003; 42 (10): 959–62.
13. Jamerson K, Bacris GL, Dahlöf B et al. ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007; 16: 80–6.
14. Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med 1995; 122 (4): 286–95.
15. Jansen RW. Postprandial hypotension: simple treatment but difficulties with the diagnosis. J Gerontol A Biol Sci Med Sci 2005; 60 (10): 1268–70.
16. Jordan J. Acute effect of water on blood pressure. What do we know? Clin Auton Res 2002; 12 (4): 250–5.
17. Jordan J. New trends in the treatment of orthostatic hypotension. Curr Hypertens Rep 2001; 3 (3): 216–26.
18. Julius S, Weber MA, Kjeldsen SE et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48 (3): 385–91.
19. Kjeldsen SE, Dahlöf B, Devereux RB et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288 (12): 1491–8.
20. Kohara K, Jiang Y, Igase M et al. Postprandial Hypotension Is Associated With Asymptomatic Cerebrovascular Damage in Essential Hypertensive Patients. Hypertens 1999; 33 (1): 565–8.
21. Kuipers HM, Jansen RW, Peeters TL et al. The influence of food temperature on postprandial blood pressure reduction and its reaction to substance-P in healthy elderly subjects. J Am Geriatr Soc 1991; 39 (2): 181–4.
22. Lahrmann H, Cortelli P, Hilz M et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006; 13: 930–6.
23. Larsen K, Hornnes N, Boysen G. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine? Stroke 2006; 37 (6): 1357–8.
24. Leenen FN, Nwachuku CE, Black HR et al. Antihypertensive and lipid-lowering treatment to prevent heart attack trial collaborative research group. Hypertension 2006; 48 (3): 374–84.
25. Lipsitz LA, Jansen RW, Connelly CM et al. Haemodynamic and neurohumoral effects of caffeine in elderly patients with symptomatic postprandial hypotension: a double-blind, randomized, placebo-controlled study. Clin Sci 1994; 87 (2): 259–67.
26. Mehagnoul-Schipper DJ, Boerman RH, Hoefnagels WH et al. Effect of levodopa on orthostatic and postprandial hypotension in elderly Parkinsonian patients. J Gerontol A Biol Sci Med Sci 2001; 56 (12): 749–55.
27. Mitro P, Feterik K, Cverckova A et al. Occurrence and relevance of postprandial hypotension in patients with essential hypertension. Wien Klin Wochenschr 1999; 23 (8): 320–5.
28. Mitro P, Feterik K, Lenartova M et al. Humoral mechanisms in the pathogenesis of postprandial hypotension in patients with essential hypertension. Wien Klin Wochenschr 2001; 113 (11): 424–32.
29. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
30. Mancia G, Bousquet P, Elghozi JL et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007; 25 (5): 909–20.
31. O'Mara G, Lyons D. Postprandial hypotension. Clin Geriatr Med 2002; 18 (2): 307–21.
32. Opie L, Shall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Call Cardiol 2002; 39: 315–22.
33. Papadopoulos D, Papademetriou V et al. Aggressive blood pressure control and stroke prevention: role of calcium channel blockers. J Hypertens 2008; 26 (5): 844–52.
34. Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med 2007; 5 (5): 444–52.
35. Psaty BM et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–44.
36. Puisieux F. Postprandial hypotension in the elderly. Presse Med 2003; 9: 1226–30.
37. Rhebergen GA, Scholzel-Dorenbos CJ. Orthostatic and postprandial hypotension in patients aged 70 years or older admitted to a medical ward. Tijdschr Gerontol Geriatr 2002; 33 (3): 119–23.
38. Russo A, Stevens JE, Wilson T et al. Guar attenuates fall in postprandial blood pressure and slows gastric emptying of oral glucose in type 2 diabetes. Dig Dis Sci 2003; 48 (7): 1221–9.
39. Sartor DM, Verberne DM. Phenotypic identification of rat rostroventrolateral medullary presympathetic vasomotor neurons inhibited by exogenous cholecystokinin. J Comp Neurol 2003; 465 (4): 467–79.
40. Sasaki E, Goda K, Nagata K et al. Acarbose improved severe postprandial hypotension in a patient with diabetes mellitus. J Diabetes Complications 2001; 15 (3): 158–61.
41. Schrader J, Lüders S, Kulschewski A et al. Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention. Stroke 2005; 36: 1218–24.
42. Shannon JR, Diedrich A, Biaggioni I et al. Water drinking as a treatment for orthostatic syndromes. Am J Med 2002; 112 (5): 355–60.
43. Shimosawa T, Kuwajima I, Suzuki Y et al. Postprandial hypotension in the elderly with and without hypertension. Nippon Ronen Igakkai Zasshi 1992; 29 (9): 661–7.
44. Staessen J et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355 (9207): 865–72.
45. Verdecchia P, Reboldi G, Angeli F et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 6: 386–92.
46. Vloet LC, Smits R, Jansen RW. The effect of meals at different mealtimes on blood pressure and symptoms in geriatric patients with postprandial hypotension. J Gerontol A Biol Sci Med Sci 2003; 58 (11): 1031–5.
47. Vloet LC, Mehagnoul-Schipper DJ, Hoefnagels WH et al. The influence of low-, normal-, and high-carbohydrate meals on blood pressure in elderly patients with postprandial hypotension. J Gerontol A Biol Sci Med Sci 2001; 56 (12): 744–8.
48. Wang JG, Li Y. Primary and secondary prevention of stroke by antihypertensive drug treatment. Expert Rev Neurother 2004; 4: 1023–31.
49. Westenend M, Lenders JW, Thien T. The course of blood pressure after a meal: a difference between young and elderly subjects. J Hypertens 1985; 3 (3): 417–9.
50. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547–59.